Hepatitis C virus treatment failure:Clinical utility for testing resistance-associated substitutions

作     者：Ezequiel Ridruejo Matias Javier Pereson Diego M Flichman Federico Alejandro Di Lello 

作者机构：Hepatology SectionDepartment of MedicineCentro de Educacion Medica e Investigaciones Clinicas Norberto Quirno“CEMIC”Ciudad Autonoma de Buenos Aires C1425ASUnspecifiedArgentina Facultad de Farmacia y BioquimicaInstituto de Investigaciones en Bacteriologea y Virologea Molecular(IBaViM)Universidad de Buenos AiresCiudad Autonoma de Buenos Aires 1113Argentina Instituto de Investigaciones Biomedicas en Retrovirus y Sindrome de Inmunodeficiencia Adquirida(INBIRS)Universidad de Buenos AiresCiudad Autonoma de Buenos Aires 1113Argentina 

出 版 物：《World Journal of Hepatology》 (世界肝病学杂志（英文版）（电子版）)

年 卷 期：2021年第13卷第9期

页      面：1069-1078页

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 100401[医学-流行病与卫生统计学] 10[医学] 

基　　金：CEMIC-CONICET 

主　　题：Hepatitis C virus Treatment failure Resistance Direct-acting antiviral 

摘      要：The hepatitis C virus has a high mutation capacity that leads to the emergence of resistance-associated substitutions(RAS).However,the consequence of resistance selection during new direct-acting antiviral drug(DAA)treatment is not necessarily the therapeutic *** fact,DAA treatment has shown a high rate(95%)of sustained virological response even when high baseline RAS prevalence has been *** the context of RAS emergence and high rates of sustained viral response,the clinical relevance of variants harboring RAS is still ***,in order to summarize the data available in international guidelines,we have reviewed the clinical utility of testing RAS in the era of new pangenotypic DAA drugs.